Success Story: NIW Approval After RFE for a Pharmacology Researcher Advancing New Treatments for Inflammation and Metabolic Diseases
Client’s Testimonial:
“Thank you again for your professional support and guidance during this process.”
On April 7th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a PhD Candidate in the Field of Pharmacology (Approval Notice).
General Field: Pharmacology
Position at the Time of Case Filing: PhD Candidate
Country of Origin: China
State of Residence at the Time of Filing: Pennsylvania
Approval Notice Date: April 7th, 2026
Processing Time: 18 months, 22 days (Premium Processing Upgrade Requested)
Case Summary:
The client’s I-140 NIW petition was approved after responding to a Request for Evidence. Holding an M.Med. in pharmaceutical science, the client built the case around a clear proposed endeavor in pharmacology: continuing research on new targets, pathways, and drugs for inflammation and metabolic-related diseases to improve treatment effectiveness and patient survival. The petition also showed that the client is currently conducting research in the field at a U.S. university and plans to continue this work in a comparable research setting.
Research Leadership and National Impact
In this case, we did not treat the client’s record as impressive on paper alone. Instead, we showed why the evidence would matter to an adjudicator under the NIW framework. The client had authored 7 peer-reviewed journal articles, including 2 first-authored papers, along with 1 first-authored conference abstract and 1 patent. Those outputs were cited 65 times, which helped demonstrate that other researchers were already relying on the client’s findings in their own work. More importantly, the petition explained that several of the client’s papers ranked among the most cited publications in Pharmacology & Toxicology for their publication years, which is a stronger indicator of field-specific influence than raw citation totals alone.
We also highlighted that the client’s work addressed serious medical needs involving inflammation, metabolic disorders, liver disease, kidney injury, lung injury, and cardiomyopathy. The significance of the client’s contributions was further supported by evidence that the research received major funding from the National Key Research and Development Program of China and the National Natural Science Foundation of China, which helped show that credible institutions had already invested in the scientific value of the work. In addition, the client had completed at least 17 peer reviews, which supported the argument that the field trusted the client’s expertise enough to evaluate the work of other researchers.
Expert Endorsements
The petition included 4 letters of recommendation from experts in the field. These letters helped connect the client’s technical record to the larger NIW standard by explaining the originality of the research, its medical relevance, and the client’s ability to continue producing useful advances in the United States. One recommender emphasized: “He will certainly contribute substantially to the well-being of American society and help sustain the USA as the leading light in world science.”
NIW Approval and Outlook
This approval, achieved despite an RFE, reflects the strength of a strategy that went beyond listing credentials. The case showed how the client’s publications, citations, peer review service, funded research, and expert support collectively established both national importance and the client’s strong positioning to advance the proposed endeavor. We are delighted that the client’s I-140 NIW petition was approved and look forward to the continued impact of this important pharmacology research in the United States.